Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
omesdafexor
- Development stage
- Phase 2
- Lead developer
- Metacrine
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MET409 (omesdafexor) is a potent and selective small molecule agonist of the farnesoid X receptor (FXR), a nuclear receptor highly expressed in the liver and intestinal tract. Developed by Metacrine for oral administration as a once-daily therapy, it is designed to treat non-alcoholic steatohepatitis (NASH) and other liver diseases. FXR activation by MET409 regulates bile acid metabolism and has anti-inflammatory and antifibrotic effects. In clinical trials, MET409 demonstrated significant reduction in liver fat content with a favorable safety profile compared to other FXR agonists. The drug does not cross-react with TGR5 or other related receptors. It has received FDA Fast Track designation for NASH due to its differentiated therapeutic profile[1][4][5][6].
- Other names
- omesdafexorMET409MET-409MET 409
02
Targets
FXR (Farnesoid x-activated receptor)
Beyond the preview
Go deeper on omesdafexor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on omesdafexor.